Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients

Objectives: Anti-TNF agents are effective to treat perianal Crohn's disease (CD). Evidence suggests that Crohn's disease patients with perianal fistulas need higher infliximab (IFX) serum concentrations compared to patients without perianal CD to achieve complete disease control. Our aim w...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of gastroenterology 2019-04, Vol.54 (4), p.453-458
Main Authors: Strik, Anne S., Löwenberg, Mark, Buskens, Christianne J., B. Gecse, Krisztina, I. Ponsioen, Cyriel, Bemelman, Willem A., D'Haens, Geert R.
Format: Article
Language:English
Subjects:
adalimumab
Adalimumab - blood
Adalimumab - therapeutic use
Adult
Anti-TNF
biologicals
Crohn Disease - blood
Crohn Disease - drug therapy
Crohn's disease
Female
fistula
Gastrointestinal Agents - blood
Gastrointestinal Agents - therapeutic use
Humans
infliximab
Infliximab - blood
Infliximab - therapeutic use
Magnetic Resonance Imaging
Male
Middle Aged
Netherlands
pharmacokinetics
Rectal Fistula - blood
Rectal Fistula - therapy
Retrospective Studies
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Wound Healing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!